EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Current Progress of Severe Fever with Thrombocytopenia Syndrome Virus (SFTSV) Vaccine Development

Dokyun Kim, Chih-Jen Lai, Inho Cha, Jae U Jung

Viruses · 16.01.2024 · 16 (1) · 128

DOI: 10.3390/v16010128 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Viruses, online erschienen am 16.01.2024. Verfasst von Dokyun Kim und 3 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Biology Department, Infection Biology Program, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA. Hauptthemen laut MEDLINE: Severe Fever with Thrombocytopenia Syndrome, Viral Vaccines. Die Arbeit wurde bisher 58-mal zitiert (Crossref) und nennt 145 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NIH HHS, National Institute of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

SFTSV is an emerging tick-borne virus causing hemorrhagic fever with a case fatality rate (CFR) that can reach up to 27%. With endemic infection in East Asia and the recent spread of the vector tick to more than 20 states in the United States, the SFTSV outbreak is a globally growing public health concern. However, there is currently no targeted antiviral therapy or licensed vaccine against SFTSV. Considering the age-dependent SFTS pathogenesis and disease outcome, a sophisticated vaccine development approach is required to safeguard the elderly population from lethal SFTSV infection. Given the recent emergence of SFTSV, the establishment of animal models to study immunogenicity and protection from SFTS symptoms has only occurred recently. The latest research efforts have applied diverse vaccine development approaches—including live-attenuated vaccine, DNA vaccine, whole inactivated virus vaccine, viral vector vaccine, protein subunit vaccine, and mRNA vaccine—in the quest to develop a safe and effective vaccine against SFTSV. This review aims to outline the current progress in SFTSV vaccine development and suggest future directions to enhance the safety and efficacy of these vaccines, ensuring their suitability for clinical application.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Severe Fever with Thrombocytopenia SyndromeViral VaccinesAgedAnimalsHumansVaccines, AttenuatedDisease OutbreaksModels, AnimalVaccine Development

Stichwörter der Autor:innen

SFTSVemerging virustick-borne diseasevaccine

Substanzen

Vaccines, AttenuatedViral Vaccines

Autor:innen und Institutionen

  • Cancer Biology Department, Infection Biology Program, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA.
  • Global Center for Pathogen and Human Health Research, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44106, USA.

Förderung

  • NIAID NIH HHS
  • NIH HHS
  • National Institute of Health

Zitieren

APA

Kim, D., Lai, C. J., Cha, I., & Jung, J. U. (2024). Current Progress of Severe Fever with Thrombocytopenia Syndrome Virus (SFTSV) Vaccine Development. Viruses, 16(1), 128. https://doi.org/10.3390/v16010128

Vancouver

Kim D, Lai CJ, Cha I, Jung JU. Current Progress of Severe Fever with Thrombocytopenia Syndrome Virus (SFTSV) Vaccine Development. Viruses. 2024;16(1):128. doi:10.3390/v16010128

BibTeX
@article{Kim2024,
  author = {Kim, Dokyun and Lai, Chih-Jen and Cha, Inho and Jung, Jae U},
  title = {Current Progress of Severe Fever with Thrombocytopenia Syndrome Virus (SFTSV) Vaccine Development},
  journal = {Viruses},
  year = {2024},
  volume = {16},
  number = {1},
  pages = {128},
  doi = {10.3390/v16010128}
}
Kostenlos starten →